The burden of depressive symptoms in people with schizophrenia.
People with schizophrenia and concurrent depressive symptoms have poorer long-term functional outcomes compared with the nondepressed. Their poorer quality of life, greater use of mental health services, and higher risk of involvement with law enforcement agencies underscore a need for special treatment interventions. Treatment of the nonpsychotic dimensions of schizophrenia is a critical part of recovery. In a 3-year study, the depressed cohort was significantly more likely than the nondepressed to use relapse-related mental health services (emergency psychiatric services, sessions with psychiatrists); to be a safety concern (violent, arrested, victimized, or suicidal); to have greater substance-related problems; and to report poorer life satisfaction, quality of life, mental functioning, family relationships, and medication adherence. Furthermore, changes in depressed status were associated with changes in functional outcomes.
Conley
Robert R
RR
Eli Lilly and Company, US Medical Division, Lilly Corporate Center, Indianapolis, IN 46285, USA. conley_robert@lilly.com
D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002985:Clinical Protocols; D015928:Cognitive Behavioral Therapy; D017281:Cost of Illness; D003863:Depression / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D000928:Antidepressive Agents; D014150:Antipsychotic Agents